MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT03244384 | ACTIVE_NOT_RECRUITING | PHASE3
739 participants

Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2017-11-03
Completion:
2026-10-31
Conditions
  • Localized Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Bladder Urothelial Carcinoma
  • Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
  • Locally Advanced Ureter Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage II Renal Pelvis and Ureter Cancer AJCC v7
  • Stage II Ureter Cancer AJCC v7
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  • Stage III Renal Pelvis and Ureter Cancer AJCC v7
  • Stage III Ureter Cancer AJCC v7
Interventions
  • PROCEDURE
  • OTHER
  • BIOLOGICAL
No Results Yet
NCT02919592 | ACTIVE_NOT_RECRUITING | NA
3603 participants

Memory Gel and Shape Combined Cohort

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2016-09-01
Completion:
2031-09-16
Conditions
  • Primary Breast Augmentation
  • Primary Breast Reconstruction
  • Revision Breast Augmentation
  • Revision Breast Reconstruction
Interventions
  • DEVICE
  • PROCEDURE
No Results Yet
NCT02867592 | ACTIVE_NOT_RECRUITING | PHASE2
109 participants

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2017-05-18
Completion:
2021-06-30
Conditions
  • Adrenal Cortical Carcinoma
  • Alveolar Soft Part Sarcoma
  • Central Nervous System Neoplasm
  • Childhood Clear Cell Sarcoma of Soft Tissue
  • Clear Cell Sarcoma of Soft Tissue
  • Ewing Sarcoma
  • Hepatoblastoma
  • Hepatocellular Carcinoma
  • Osteosarcoma
  • Recurrent Adrenal Cortical Carcinoma
  • Recurrent Alveolar Soft Part Sarcoma
  • Recurrent Clear Cell Sarcoma of Soft Tissue
  • Recurrent Ewing Sarcoma
  • Recurrent Hepatoblastoma
  • Recurrent Hepatocellular Carcinoma
  • Recurrent Kidney Wilms Tumor
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Osteosarcoma
  • Recurrent Primary Malignant Central Nervous System Neoplasm
  • Recurrent Renal Cell Carcinoma
  • Recurrent Rhabdomyosarcoma
  • Recurrent Soft Tissue Sarcoma
  • Recurrent Thyroid Gland Medullary Carcinoma
  • Refractory Adrenal Cortical Carcinoma
  • Refractory Alveolar Soft Part Sarcoma
  • Refractory Clear Cell Sarcoma of Soft Tissue
  • Refractory Ewing Sarcoma
  • Refractory Hepatoblastoma
  • Refractory Hepatocellular Carcinoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Osteosarcoma
  • Refractory Primary Central Nervous System Neoplasm
  • Refractory Primary Malignant Central Nervous System Neoplasm
  • Refractory Renal Cell Carcinoma
  • Refractory Rhabdomyosarcoma
  • Refractory Soft Tissue Sarcoma
  • Refractory Thyroid Gland Medullary Carcinoma
  • Refractory Wilms Tumor
  • Renal Cell Carcinoma
  • Rhabdomyosarcoma
  • Soft Tissue Sarcoma
  • Solid Neoplasm
  • Thyroid Gland Medullary Carcinoma
  • Wilms Tumor
Interventions
  • DRUG
  • OTHER
Results Available
NCT02839707 | ACTIVE_NOT_RECRUITING | PHASE2/PHASE3
444 participants

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2017-06-23
Completion:
2023-05-09
Conditions
  • Fallopian Tube High Grade Serous Adenocarcinoma
  • Ovarian High Grade Serous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • DRUG
  • BIOLOGICAL
  • PROCEDURE
  • OTHER
Results Available
NCT02639325 | RECRUITING
100 participants

Tumor Related Epilepsy

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-28
Start Date:
2016-01-26
Completion:
2032-07-01
Conditions
  • Epilepsy
  • Cancer
  • Brain Neoplasm
No Results Yet
NCT02595944 | ACTIVE_NOT_RECRUITING | PHASE3
903 participants

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2016-07-22
Completion:
2026-12-31
Conditions
  • Stage IB Lung Non-Small Cell Carcinoma AJCC v7
  • Stage II Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
No Results Yet
NCT02567435 | ACTIVE_NOT_RECRUITING | PHASE3
325 participants

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2016-06-01
Completion:
2023-06-30
Conditions
  • Alveolar Rhabdomyosarcoma
  • Botryoid-Type Embryonal Rhabdomyosarcoma
  • Embryonal Rhabdomyosarcoma
  • Rhabdomyosarcoma
  • Sclerosing Rhabdomyosarcoma
  • Spindle Cell Rhabdomyosarcoma
Interventions
  • DRUG
  • BIOLOGICAL
  • OTHER
  • RADIATION
Results Available
NCT02506153 | ACTIVE_NOT_RECRUITING | PHASE3
1301 participants

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-28
Start Date:
2015-11-10
Completion:
2023-09-15
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Metastatic Cutaneous Melanoma
  • Metastatic Mucosal Melanoma
  • Metastatic Non-Cutaneous Melanoma
  • Non-Cutaneous Melanoma
  • Recurrent Cutaneous Melanoma
  • Recurrent Mucosal Melanoma
  • Recurrent Non-Cutaneous Melanoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
  • OTHER
Results Available
Previous
Sorted by latest updates
Next
Showing 40 trials per page